ArticleInternational journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases2021
Clinical and public health utility of Mycobacterium tuberculosis whole genome sequencing.
Article in International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 32 citations in OpenAlex.
- The Impact of Adopting Whole-Genome Sequencing for Tuberculosis Diagnosis in China: A Cost-Effectiveness Analysis.Open forum infectious diseases · 2026Article
- Whole genome sequencing for Mycobacterium tuberculosis in public health responses: a review of current practice and enablers in select low-incidence jurisdictions.BMC public health · 2026Review
- The public health utility of whole genome sequencing: Insights from a tuberculosis outbreak in Australia and perspectives of public health professionals.PLOS global public health · 2026Article
- Spatio-temporal patterns of tuberculosis revealed by routineThe Lancet regional health. Western Pacific · 2026Article
- Characterizing the Etiology of Recurrent Tuberculosis Using Whole Genome Sequencing: Alaska, 2008-2020.The Journal of infectious diseases · 2025Article
- Diagnosing Tuberculosis: Traditional and New Methods Against an Old Enemy.Journal of clinical practice and research · 2024Review
- Clinical application of whole-genome sequencing in the management of extensively drug-resistant tuberculosis: a case report.Annals of clinical microbiology and antimicrobials · 2024Article
- Assessment of the pathogen genomics landscape highlights disparities and challenges for effective AMR Surveillance and outbreak response in the East African community.BMC public health · 2024Article
- Pangenome databases improve host removal and mycobacteria classification from clinical metagenomic data.GigaScience · 2024Article
- Exploring programmatic indicators of tuberculosis control that incorporate routineThe Lancet regional health. Western Pacific · 2023Article
- Implementation of national whole-genome sequencing ofMicrobial genomics · 2023Article
- Clinical Whole-Genome Sequencing Assay for RapidMicroorganisms · 2023Article
- Advancing tuberculosis management: the role of predictive, preventive, and personalized medicine.Frontiers in microbiology · 2023Review
- Whole genome sequencing ofFrontiers in microbiology · 2023Article
- Whole genome sequencing for tuberculosis in Victoria, Australia: A genomic implementation study from 2017 to 2020.The Lancet regional health. Western Pacific · 2022Article
- Review
- TBProfiler for automated calling of the association with drug resistance of variants in Mycobacterium tuberculosis.PloS one · 2022Article
- Article
- World Tuberculosis Day 2021 Theme - 'The Clock is Ticking' - and the world is running out of time to deliver the United Nations General Assembly commitments to End TB due to the COVID-19 pandemic.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2021Article
- Implementation of whole genome sequencing for tuberculosis diagnostics in a low-middle income, high MDR-TB burden country.Scientific reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
The World Health Organization (WHO) estimates that around 10 million people develop tuberculosis (TB) every year, with 1.5 million deaths attributed to TB in 2019 (World Health Organization, 2020). The majority of the disease burden occurs in low-income countries, where access to diagnostics and tailored treatment remains problematic. The current COVID-19 pandemic further threatens to impact global TB control by diverting resources, reducing notifications and hence significantly increasing deaths attributable to TB (World Health Organization, 2020). Whole genome sequencing (WGS) is becoming increasingly accessible, and has particular value in the diagnosis and management of TB disease (Cabibbe et al., 2018; Meehan et al., 2019). Not only does it have the potential to give more rapid and complete information on drug-resistance, but the high discriminatory power it offers allows detection of clusters and transmission pathways, as well as likely contamination events, mixed infections and to differentiate between re-infection and relapse with much greater confidence than previous typing methods.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.